What You Should Know:
– SamaCare, a cloud-based patient access platform for specialty medications, today announced that it has closed an oversubscribed $17 million Series B investment round led by new investor Questa Capital.
– Questa is joined in the round by existing investors Vive Collective and South Park Commons.
SamaCare Secures New Investment to Enhance Patient Access Platform and Streamline Healthcare Processes
SamaCare will use this new round of investment to accelerate the development of its one-stop patient access platform, designed to save healthcare organizations time and resources while ensuring patients receive therapy sooner.
This latest investment follows SamaCare’s success in streamlining patient access to treatments, initially addressing the cumbersome prior authorization process. Prior authorizations, required by many health plans before a patient can use specific drugs, are often manual and paper-heavy. The lack of standardized requirements and processes for prior authorizations across commercial plans results in fragmented, inconsistent, and analog management, causing treatment delays and burdens for providers, patients, health plans, and other stakeholders.
With the investment, SamaCare will build the comprehensive Script-to-Therapy Operating System™, enhancing its platform to better serve patients, providers, and pharmaceutical companies through:
1. Expanding beyond prior authorizations to create a seamless, digital, post-prescription workflow.
2. Improving collaboration among healthcare teams within and between provider offices.
3. Using AI to reduce administrative delays and eliminate tedious paperwork.
4. Developing a data insights engine for a faster, more effective Script-to-Therapy journey.
SamaCare enables pharmaceutical manufacturers, providers, payors, and other stakeholders to deliver life-changing therapies to patients quickly and cost-effectively. The company offers a cloud-based workflow automation platform that streamlines specialty drug prior authorization, enrollment, and benefit verification for medical practices. Additionally, SamaCare provides premium services and data analytics for pharmaceutical brands to improve access to therapy.
“By digitizing the current manual paper-and-fax-heavy process, our platform reduces the administrative burdens that harm patient care, drive healthcare providers crazy, and raise costs for the system,” said Syam Palakurthy, founder and CEO of SamaCare. “The support of Questa Capital and our current investors will help us accelerate much-needed change to a cumbersome system.”
